SK Biopharmaceuticals Co Ltd-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:SK Biopharmaceuticals Co Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013461
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:23
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:韓国
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
SK Biopharmaceuticals Co Ltd (SK Biopharmaceuticals), a subsidiary of SK Holdings Co Ltd is a developer of drug candidates. The company develops and markets innovative drugs for the treatment of central nervous system. It offers plumiaz, SKL-N05 and JZP-110; YKP3089, relenopride, SKL-PD, SKL-A4R, SKL-PSY and FZ-016; SKL-ADHD and carisbamate drugs. SK Biopharmaceuticals provides research and development; biological studies, preclinical studies, lead compound development, and phase development services. The company offers development of next-generation drugs that maintains efficacy and minimizes side-effects and toxicity by harnessing life science technologies in new drug and development programs. It has developed drug candidates in the area of CNS such as epilepsy and GI with chronic constipation and constipation dominant irritable bowel syndrome. The company operates through its research centers in Daejeon. SK Biopharmaceuticals is headquartered in Seongnam, South Korea.

SK Biopharmaceuticals Co Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
SK Biopharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
SK Biopharmaceuticals Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
SK Biopharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
SK Biopharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
SK Biopharmaceuticals Co Ltd, Medical Devices Deals, 2011 to YTD 2017 9
SK Biopharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
SK Biopharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
SK Biopharma And AriBio Enter Into Co-Development Agreement For SKL-G 11
SK Biopharma Enters Into Co-Development Agreement With SK Chemicals For YKP-10811 12
SK Biopharma Enters Into Co-Development Agreement With PKU International HealthCare And Shanghai Medicilon 13
SK BioPharma Enters Co-Development Agreement With Shanghai Meidiclon 14
Mayo Clinic Enters Into Research Agreement With SK BioPharma 15
Acquisition 16
SK Holdings Acquires SK Biotech from SK Biopharma 16
SK Biopharmaceuticals Co Ltd – Key Competitors 17
SK Biopharmaceuticals Co Ltd – Key Employees 18
SK Biopharmaceuticals Co Ltd – Locations And Subsidiaries 19
Head Office 19
Other Locations & Subsidiaries 19
Recent Developments 20
Clinical Trials 20
Sep 26, 2016: Jazz Pharmaceuticals Announces That Patient Enrollment is Complete for the Phase 3 Studies of JZP-110 Evaluating Excessive Sleepiness in Obstructive Sleep Apnea 20
Jun 14, 2016: Jazz Pharmaceuticals Presents New Data from a Human Abuse Liability Study for JZP-110, an Investigational Treatment for Excessive Sleepiness in Patients with Narcolepsy or with Obstructive Sleep Apnea, at 30th Annual SLEEP Meeting 21
Appendix 23
Methodology 23
About GlobalData 23
Contact Us 23
Disclaimer 23

List of Tables
SK Biopharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Key Facts 2
SK Biopharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
SK Biopharmaceuticals Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
SK Biopharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
SK Biopharmaceuticals Co Ltd, Deals By Therapy Area, 2011 to YTD 2017 8
SK Biopharmaceuticals Co Ltd, Medical Devices Deals, 2011 to YTD 2017 9
SK Biopharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
SK Biopharma And AriBio Enter Into Co-Development Agreement For SKL-G 11
SK Biopharma Enters Into Co-Development Agreement With SK Chemicals For YKP-10811 12
SK Biopharma Enters Into Co-Development Agreement With PKU International HealthCare And Shanghai Medicilon 13
SK BioPharma Enters Co-Development Agreement With Shanghai Meidiclon 14
Mayo Clinic Enters Into Research Agreement With SK BioPharma 15
SK Holdings Acquires SK Biotech from SK Biopharma 16
SK Biopharmaceuticals Co Ltd, Key Competitors 17
SK Biopharmaceuticals Co Ltd, Key Employees 18
SK Biopharmaceuticals Co Ltd, Subsidiaries 19

★海外企業調査レポート[SK Biopharmaceuticals Co Ltd-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Exact Sciences Corp (EXAS):製薬・医療:M&Aディール及び事業提携情報
    Summary Exact Sciences Corp (Exact Sciences) is a molecular diagnostic company that focuses on the early detection and prevention of various types of cancers. The company’s flagship product, Cologuard test is a non-invasive stool-based deoxyribonucleic acid (DNA) screening product indicated for the …
  • Hindalco Industries Ltd:企業の戦略・SWOT・財務情報
    Hindalco Industries Ltd - Strategy, SWOT and Corporate Finance Report Summary Hindalco Industries Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Intrasense SA (ALINS):企業の財務・戦略的SWOT分析
    Summary Intrasense SA (Intrasense) is a healthcare technology company that offers software solution for analysis and visualisation of medical images. The company offers a range of clinical apps such as lesion tracking solution, analysis tools, virtual colonoscopy, and lung nodule follow-up software, …
  • Qatar Holding LLC:企業のM&A・事業提携・投資動向
    Qatar Holding LLC - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Qatar Holding LLC Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), div …
  • Eagle Cement Corporation (EAGLE):企業の財務・戦略的SWOT分析
    Eagle Cement Corporation (EAGLE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Citrix Systems Inc (CTXS):企業の財務・戦略的SWOT分析
    Citrix Systems Inc (CTXS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Itausa – Investimentos Itau SA (ITSA4):企業の財務・戦略的SWOT分析
    Itausa - Investimentos Itau SA (ITSA4) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths a …
  • Tsurumi Manufacturing Co Ltd (6351):企業の財務・戦略的SWOT分析
    Tsurumi Manufacturing Co Ltd (6351) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Formosa Petrochemical Corp (6505):企業の財務・戦略的SWOT分析
    Formosa Petrochemical Corp (6505) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Dance Biopharm Inc:医療機器:M&Aディール及び事業提携情報
    Summary Dance Biopharm Inc (Dance Biopharm), a subsidiary of Dance Biopharm Holdings Inc, formerly Dance Pharmaceuticals Inc, is a biotechnology company that develops inhaled insulin products to treat diabetes patients. The company provides product pipeline such as Dance-501, a pocket-sized inhaler …
  • Platte River Power Authority:発電所・企業SWOT分析
    Platte River Power Authority - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key …
  • Bancolombia SA (BCOLOMBIA):企業の財務・戦略的SWOT分析
    Bancolombia SA (BCOLOMBIA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Eyevensys SAS:製薬・医療:M&Aディール及び事業提携情報
    Summary Eyevensys SAS (Eyevensys) is a clinical stage biotechnology company developing non-viral gene therapies for ophthalmic diseases. Its lead product, EYS-606, is a soluble TNFa receptor plasmid associated with the ETIS device to treat non-infectious intermediate and posterior uveitis(NIU); EYS- …
  • Jyoti Structures Ltd (JYOTISTRUC)-エネルギー分野:企業M&A・提携分析
    Summary Jyoti Structures Ltd (JSL) is a turnkey engineering, procurement, and construction (EPC) services provider that designs, tests, manufactures, sources, constructs, and supplies transmission lines, substations, and microwave towers. It designs HVDC and river crossing transmission towers, subst …
  • Ethypharm SA:製薬・医療:M&Aディール及び事業提携情報
    Summary Ethypharm SA (Ethypharm), a subsidiary of Astorg Partners is a pharmaceutical company that develops and manufactures drugs for the treatment of pain, gastrointestinal, cancer, cardiovascular and central nervous system diseases. The company provides products such as ibuprofen, paracetamol, pr …
  • Eesti Energia AS:企業の戦略・SWOT・財務情報
    Eesti Energia AS - Strategy, SWOT and Corporate Finance Report Summary Eesti Energia AS - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • GN Store Nord AS (GN):企業の財務・戦略的SWOT分析
    GN Store Nord AS (GN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • NeuroGenetic Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary NeuroGenetic Pharmaceuticals Inc (NeuroGenetic Pharmaceuticals) is a pharmaceutical company that develops drugs for Alzheimer’s diseases. The company develops products with its gamma-secretase modulators technology. It applies multiple lead compounds for the treatment of neurodegenerative co …
  • Rossiiskie Zheleznye Dorogi:企業の戦略・SWOT・財務情報
    Rossiiskie Zheleznye Dorogi - Strategy, SWOT and Corporate Finance Report Summary Rossiiskie Zheleznye Dorogi - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Oxford Nanopore Technologies Ltd-医療機器分野:企業M&A・提携分析
    Summary Oxford Nanopore Technologies Ltd (Oxford Nanopore), formerly Oxford NanoLabs Ltd., is a biotechnology diagnostic company. It develops technologies for molecular detection and analysis. The company offers a range of nanopores and devices such as MinION, PromethION and GridION used for the ana …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆